Compare Sana Biotechnology Inc (SANA) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs J M Smucker Co — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while J M Smucker Co trades at $112.69 (market cap $11.97B). The key difference: J M Smucker Co is far larger — about 13.7× Sana Biotechnology Inc's market cap, and J M Smucker Co pays a 3.93% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SJM | |
|---|---|---|
Market Cap | $873.84M | $11.97B |
Sector | Health | Consumer Staples |
52-Week High | $5.92 | $117.05 |
52-Week Low | $2.68 | $89.53 |
Enterprise Value | $848.03M | $19.00B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
SJM trades at $115.75, up 3.34% today, showing strong momentum near resistance levels. The company maintains positive cash flow despite recent net losses, with operating cash flow of $1.21 billion in 2025. Recent dividend increases and analyst consensus support a bullish outlook, though profitability metrics remain challenged with negative ROE and net margins. Technical indicators show bullish momentum with the stock trading above key moving averages.
The investment case balances strong cash generation and dividend growth against profitability challenges. Analyst consensus targets $125.50 with 52% buy ratings, suggesting 8.4% upside potential. Key risks include persistent negative margins, high debt levels at 43.7% debt-to-asset ratio, and competitive pressures in the consumer staples sector. The company's Uncrustables division remains a key growth driver with nearly $1 billion in annual sales.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
